Tebonin 240 mg is a prescription medication containing amlodipine besylate, a calcium channel blocker used to treat high blood pressure and certain types of chest pain (angina). It works by relaxing blood vessels, reducing strain on the heart and improving blood flow.
Amlodipine belongs to a class of drugs that block calcium from entering muscle cells in the heart and blood vessel walls. This action causes the vessels to widen, lowering resistance and reducing blood pressure. The 240 mg strength is not standard-most formulations are 5 mg, 10 mg, or 20 mg. A 240 mg tablet likely contains 20 mg of amlodipine, with the remainder being inactive ingredients. The dosage strength is often misstated due to labeling confusion or incorrect referencing.
According to the U.S. Food and Drug Administration (FDA), amlodipine is approved for treating hypertension and chronic stable angina. The recommended starting dose is typically 5 mg once daily, with adjustments based on response. A 240 mg tablet would be an unusually high dose unless prescribed under specific clinical circumstances. Misreading the label or confusing the tablet's imprint code can lead to dangerous errors.
Tebonin 240 mg functions by inhibiting L-type calcium channels in vascular smooth muscle and cardiac tissue. Calcium influx triggers muscle contraction. By blocking this pathway, amlodipine reduces vascular tone and decreases cardiac workload. This lowers systemic vascular resistance and improves coronary blood flow.
The drug takes effect within 6 to 12 hours after ingestion. Peak plasma concentrations occur around 6 to 12 hours post-dose. Its half-life is approximately 35 to 50 hours, allowing for once-daily administration. Because of its long duration, patients may notice blood pressure reductions within 1 to 2 weeks of consistent use.
For example, a 62-year-old male with stage 2 hypertension (BP consistently above 160/100 mmHg) was prescribed Tebonin 240 mg (20 mg amlodipine) daily. After four weeks, his systolic pressure dropped from 168 mmHg to 132 mmHg, and diastolic from 102 mmHg to 80 mmHg. This response aligns with clinical trial data showing average systolic reduction of 10-15 mmHg and diastolic reduction of 5-10 mmHg over 4-8 weeks.
While Tebonin 240 mg is marketed as a brand-name product, it is chemically equivalent to generic amlodipine. The following table shows common amlodipine formulations:
| Strength | Active Ingredient | Common Brand Names | Typical Use |
|---|---|---|---|
| 5 mg | amlodipine besylate | Norvasc, Tebonin 5 mg | First-line hypertension therapy |
| 10 mg | amlodipine besylate | Norvasc, Tebonin 10 mg | Higher blood pressure control |
| 20 mg | amlodipine besylate | Norvasc, Tebonin 20 mg | Resistant hypertension cases |
There is no FDA-approved formulation of amlodipine at 240 mg. The "240" on the pill likely indicates the tablet's imprint code, not the milligram amount. For example, a 20 mg tablet may be marked "T240" to denote manufacturer batch or identification. Confusing the imprint with the actual dose is a known risk in medication safety reports.
The National Institute of Health (NIH) warns that misidentification of pills due to similar appearance or labeling is a leading cause of medication errors. In one study, 12% of medication-related adverse events involved patients mistaking a 5 mg tablet for a 20 mg version. Always verify the drug's strength with a pharmacist or through the FDA's Pill Identifier tool.
Tebonin 240 mg is prescribed primarily for adults with uncontrolled hypertension despite lifestyle changes or prior therapy. It is also used off-label in patients with vasospastic angina (Prinzmetal's angina), where coronary artery spasm leads to ischemia. Amlodipine's ability to relax coronary arteries makes it effective in preventing such episodes.
It is not used for acute conditions like hypertensive crisis. In those cases, intravenous agents like labetalol or nitroprusside are preferred. Tebonin 240 mg is intended for maintenance therapy, not emergency care.
One patient with diabetes and hypertension reported improved glycemic control after starting amlodipine. While not a direct effect, reduced blood pressure can lower cardiovascular strain, indirectly supporting metabolic health. However, amlodipine may slightly increase the risk of edema, particularly in older adults. Monitoring for swelling in ankles or feet is essential during early treatment.
Many users assume that higher dose equals better results. This is false. Increasing amlodipine beyond 10 mg does not improve efficacy but raises the risk of side effects. The FDA states that doses above 10 mg offer no additional benefit over 10 mg in most patients.
Another misconception is that Tebonin 240 mg can be used interchangeably with other blood pressure medications. It cannot. Combining amlodipine with beta-blockers or ACE inhibitors requires careful monitoring. For example, combining it with metoprolol increases the risk of bradycardia and hypotension. Patients on multiple antihypertensives must have regular blood pressure checks.
One non-obvious fact: amlodipine may cause gingival hyperplasia (overgrowth of gum tissue) in rare cases. This side effect occurs in less than 1% of users but is more common in patients with poor oral hygiene. Regular dental visits are advised during long-term use.
A 58-year-old woman with a history of migraines and hypertension was prescribed Tebonin 240 mg (20 mg amlodipine) after her previous regimen of lisinopril failed to control her BP. Her baseline readings were 158/96 mmHg. After two weeks on the new medication, her BP stabilized at 130/82 mmHg. She reported mild ankle swelling after three days, which resolved with elevation and compression socks.
Her doctor adjusted her dose to 10 mg daily after six weeks, maintaining control. The patient continued to monitor her blood pressure at home and reported no dizziness or fatigue. This case illustrates the importance of titrating dose to effect and managing side effects proactively.
Understanding the correct use of Tebonin 240 mg prevents misuse and supports safe, effective management of hypertension. Always follow your prescriber's instructions and report unusual symptoms promptly.